Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
treatment crawled date : 2021 - 04 - 15 save search
Biogen Grows Presence in China with the Approval of TECFIDERA® (dimethyl fumarate) for the Treatment of Relapsing Multiple Sclerosis
Published: 2021-04-15 (Crawled : 21:00) - globenewswire.com
BIIB | $194.39 2.03% 1.99% 1.6M
|
Health Technology
|
| O: 0.06%
H: 1.19%
C: -0.11%
multiple sclerosis treatment china sclerosis approval
FibroGen Receives Rare Pediatric Disease Designation from the U.S. FDA for Pamrevlumab for the Treatment of Duchenne Muscular Dystrophy
Published: 2021-04-15 (Crawled : 14:15) - biospace.com/
FGEN | $1.15 -1.71% -1.74% 1.3M
|
Health Technology
|
| O: 0.52%
H: 3.25%
C: -0.31%
disease treatment fda rare pediatric disease designation duchenne designation rare
electroCore Announces Publication in Nature Reviews: Neurology Highlighting the Role of Non-Invasive Vagus Nerve Stimulation (nVNS) as an Emerging Treatment for Cluster Headache
Published: 2021-04-15 (Crawled : 14:00) - biospace.com/
ECOR | $6.0 6.38% 6.0% 7.4K
|
Health Technology
|
| O: 1.1%
H: 0.16%
C: -4.35%
treatment
GSK and Vir Biotechnology Announce EMA Review of Dual-Action Monoclonal Antibody VIR-7831 for the Early Treatment of COVID-19
Published: 2021-04-15 (Crawled : 14:00) - globenewswire.com
GSK | News | $39.75 1.22% 0.0% 1.6M
|
Health Technology
|
| O: 4.23%
H: 1.59%
C: 0.08%
VIR | $7.96 0.0% 1.1M
|
Health Technology
|
| O: 0.37%
H: 2.8%
C: -1.49%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 0.76%
H: 0.61%
C: 0.14%
covid treatment antibody biotech technology iot ema
Pulmatrix Hosting Key Opinion Webinar on PUR3100 (Orally Inhaled DHE) Therapy for the Treatment of Acute Migraine
Published: 2021-04-15 (Crawled : 13:15) - ir.pulmatrix.com
PULM | $2.0 2.04% 2.0% 12K
|
Health Technology
|
| O: -0.97%
H: 0.84%
C: -8.27%
treatment migraine therapy
Health Canada Authorizes EVRYSDI (risdiplam) for the treatment of spinal muscular atrophy (SMA) in adults and children
Published: 2021-04-15 (Crawled : 13:15) - biospace.com/
ARVL | News | $0.49 0.37% 2.5M
|
Manufacturing
|
| O: 4.02%
H: 0.0%
C: -11.6%
treatment children authorized muscular atrophy
BioMarin Announces New and Updated Data at 2021 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting Demonstrating Commitment to Understanding Achondroplasia and Potential Treatment Choice
Published: 2021-04-15 (Crawled : 13:00) - investors.biomarin.com
ICLR | $288.32 -1.2% -1.21% 640K
|
Health Technology
|
| O: 1.5%
H: 3.57%
C: 2.92%
BMRN | $88.68 -1.54% -1.57% 1.8M
|
Health Technology
|
| O: -1.94%
H: 3.81%
C: 2.68%
treatment genetic potential drop genomic achondroplasia
Regulus Therapeutics Announces Completion of Dosing in the First Cohort of Phase 1b Clinical Trial of RGLS4326 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Published: 2021-04-15 (Crawled : 13:00) - biospace.com/
RGLS | $2.13 -4.05% -4.23% 220K
|
Health Technology
|
| O: -0.74%
H: 8.89%
C: 3.7%
disease treatment phase 1 trial phase 1b kidney phase 2b
Continued Improvements in Motor Milestones in Infants with Type 1 Spinal Muscular Atrophy After Two Years of Treatment with Evrysdi™
Published: 2021-04-15 (Crawled : 06:00) - prnewswire.com
PTCT | News S | $25.32 2.55% 2.49% 3.9M
|
Health Technology
|
| O: 0.69%
H: 4.21%
C: -0.08%
treatment milestone muscular atrophy
Bristol Myers Squibb Receives European Commission Approval for Opdivo® (nivolumab) in Combination with Cabometyx® (cabozantinib) as First-Line Treatment for Patients with Advanced Renal Cell Carcinoma
Published: 2021-04-14 (Crawled : 00:00) - biospace.com/
TAK | News | $13.24 0.61% 0.0% 1.3M
|
Health Technology
|
| O: 0.0%
H: 1.09%
C: 0.35%
BMY | $48.93 1.3% 0.0% 10M
|
Health Technology
|
| O: 0.27%
H: 0.33%
C: 0.09%
EXEL | $22.51 0.09% 0.09% 2.3M
|
Health Technology
|
| O: -0.38%
H: 4.2%
C: 3.09%
treatment europe renal approval cell carcinoma nivolumab
REGENXBIO Announces Dosing of First Patient in Cohort 3 of Phase I/II Trial of RGX-121 for the Treatment of MPS II (Hunter Syndrome)
Published: 2021-04-14 (Crawled : 00:00) - biospace.com/
RGNX | $15.67 -2.73% -2.87% 570K
|
Health Technology
|
| O: 0.69%
H: 3.87%
C: 1.26%
treatment trial syndros mps-ih
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
Your saved searches
Save your searches and get alerts when important news are released.